secwatch.observer — SEC 8-K summary
======================================

Issuer:     BriaCell Therapeutics Corp. (BCTX)
CIK:        0001610820
Form:       8-K
Filed at:   2023-12-20T23:59:59+00:00
Accession:  0001493152-23-045569
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BriaCell reports prelim OS up to 2x literature in ADC-refractory breast cancer subset
--------------------------------------------------------------------------------

- 23 heavily pre-treated (median 6 prior therapies) advanced breast cancer patients, all failed ADCs (KADCYLA, ENHERTU, TRODELVY).
- Median OS up to twice that reported in comparable studies; 17 of 23 patients remain alive.
- Disease control rate of 40% in evaluable patients; PFS similar or better than last regimen in 40%.
- No toxicity-related discontinuations and no cases of Interstitial Lung Disease (ILD) with Bria-IMT regimen.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1610820/000149315223045569/0001493152-23-045569-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1610820/000149315223045569/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-045569

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer